A vaccine developed in Jiangsu involves neutralising antibodies targeting epitopes located on different domains of the spike protein of the coronavirus. Photo: AFP A vaccine developed in Jiangsu involves neutralising antibodies targeting epitopes located on different domains of the spike protein of the coronavirus. Photo: AFP
A vaccine developed in Jiangsu involves neutralising antibodies targeting epitopes located on different domains of the spike protein of the coronavirus. Photo: AFP

Chinese firm puts Covid-19 vaccine to landmark test in New Zealand

  • Health official says it is the first time a vaccine created wholly in China has been used in human trials in a developed country
  • Shot performed strongly in animal studies, researcher says

Topic |   Coronavirus pandemic
A vaccine developed in Jiangsu involves neutralising antibodies targeting epitopes located on different domains of the spike protein of the coronavirus. Photo: AFP A vaccine developed in Jiangsu involves neutralising antibodies targeting epitopes located on different domains of the spike protein of the coronavirus. Photo: AFP
A vaccine developed in Jiangsu involves neutralising antibodies targeting epitopes located on different domains of the spike protein of the coronavirus. Photo: AFP

Corrected [6:44pm, 23 Jun, 2021]

  • [6:44pm, 23 Jun, 2021]

    An earlier version of this story incorrectly reported that other Chinese vaccine makers including Clover and Advaccine had conducted human trials in Austria. The story has been amended to reflect that they took place in Australia.

  • We are part of the Trust Project What is it?
READ FULL ARTICLE